HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: M700071-JLR200v1 48/7/1488    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Qian, Y.-W. Articles by Cao, G. Search for Related Content PubMed PubMed Citation Articles by Qian, Y.-W. Articles by Cao, G. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol. 48, 1488-1498, July 2007
Copyright © 2007 by American Society for Biochemistry and Molecular Biology

Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis

Yue-Wei Qian¹, Robert J. Schmidt¹, Youyan Zhang¹, Shaoyou Chu, Aimin Lin, He Wang, Xiliang Wang, Thomas P. Beyer, William R. Bensch, Weiming Li, Mariam E. Ehsani, Deshun Lu, Robert J. Konrad, Patrick I. Eacho, David E. Moller, Sotirios K. Karathanasis and Guoqing Cao²

Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, IN 46285

Published, JLR Papers in Press, April 20, 2007.

¹ Y-W. Qian, R. J. Schmidt, and Y. Zhang contributed equally to this work.

² To whom correspondence should be addressed. e-mail: guoqing_cao{at}lilly.com

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protease that regulates low density lipoprotein receptor (LDLR) protein levels. The mechanisms of this action, however, remain to be defined. We show here that recombinant human PCSK9 expressed in HEK293 cells was readily secreted into the medium, with the prosegment associated with the C-terminal domain. Secreted PCSK9 mediated cell surface LDLR degradation in a concentration- and time-dependent manner when added to HEK293 cells. Accordingly, cellular LDL uptake was significantly reduced as well. When infused directly into C57B6 mice, purified human PCSK9 substantially reduced hepatic LDLR protein levels and resulted in increased plasma LDL cholesterol. When added to culture medium, fluorescently labeled PCSK9 was endocytosed and displayed endosomal-lysosomal intracellular localization in HepG2 cells, as was demonstrated by colocalization with DiI-LDL. PCSK9 endocytosis was mediated by LDLR as LDLR deficiency (hepatocytes from LDLR null mice), or RNA interference-mediated knockdown of LDLR markedly reduced PCSK9 endocytosis. In addition, RNA interference knockdown of the autosomal recessive hypercholesterolemia (ARH) gene product also significantly reduced PCSK9 endocytosis. Biochemical analysis revealed that the LDLR extracellular domain interacted directly with secreted PCSK9; thus, overexpression of the LDLR extracellular domain was able to attenuate the reduction of cell surface LDLR levels by secreted PCSK9. Together, these results reveal that secreted PCSK9 retains biological activity, is able to bind directly to the LDLR extracellular domain, and undergoes LDLR-ARH-mediated endocytosis, leading to accelerated intracellular degradation of the LDLR.

Supplementary key words proprotein convertase subtilisin/kexin type 9

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. S. Troutt, W. E. Alborn, G. Cao, and R. J. Konrad Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels J. Lipid Res., February 1, 2010; 51(2): 345 - 351. [Abstract] [Full Text] [PDF]

				S. Poirier, G. Mayer, V. Poupon, P. S. McPherson, R. Desjardins, K. Ly, M.-C. Asselin, R. Day, F. J. Duclos, M. Witmer, et al. Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation: EVIDENCE FOR AN INTRACELLULAR ROUTE J. Biol. Chem., October 16, 2009; 284(42): 28856 - 28864. [Abstract] [Full Text] [PDF]

				H. Li, B. Dong, S. W. Park, H.-S. Lee, W. Chen, and J. Liu Hepatocyte Nuclear Factor 1{alpha} Plays a Critical Role in PCSK9 Gene Transcription and Regulation by the Natural Hypocholesterolemic Compound Berberine J. Biol. Chem., October 16, 2009; 284(42): 28885 - 28895. [Abstract] [Full Text] [PDF]

				Y. Luo, L. Warren, D. Xia, H. Jensen, T. Sand, S. Petras, W. Qin, K. S. Miller, and J. Hawkins Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice J. Lipid Res., August 1, 2009; 50(8): 1581 - 1588. [Abstract] [Full Text] [PDF]

				J. C. Y. Chan, D. E. Piper, Q. Cao, D. Liu, C. King, W. Wang, J. Tang, Q. Liu, J. Higbee, Z. Xia, et al. From the Cover: A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates PNAS, June 16, 2009; 106(24): 9820 - 9825. [Abstract] [Full Text] [PDF]

				M. C. McNutt, H. J. Kwon, C. Chen, J. R. Chen, J. D. Horton, and T. A. Lagace Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells J. Biol. Chem., April 17, 2009; 284(16): 10561 - 10570. [Abstract] [Full Text] [PDF]

				J. D. Horton, J. C. Cohen, and H. H. Hobbs PCSK9: a convertase that coordinates LDL catabolism J. Lipid Res., April 1, 2009; 50(Supplement): S172 - S177. [Abstract] [Full Text] [PDF]

				L. Persson, C. Galman, B. Angelin, and M. Rudling Importance of Proprotein Convertase Subtilisin/Kexin Type 9 in the Hormonal and Dietary Regulation of Rat Liver Low-Density Lipoprotein Receptors Endocrinology, March 1, 2009; 150(3): 1140 - 1146. [Abstract] [Full Text] [PDF]

				S. Pandit, D. Wisniewski, J. C. Santoro, S. Ha, V. Ramakrishnan, R. M. Cubbon, R. T. Cummings, S. D. Wright, C. P. Sparrow, A. Sitlani, et al. Functional analysis of sites within PCSK9 responsible for hypercholesterolemia J. Lipid Res., June 1, 2008; 49(6): 1333 - 1343. [Abstract] [Full Text] [PDF]

				G. Lambert, N. Ancellin, F. Charlton, D. Comas, J. Pilot, A. Keech, S. Patel, D. R. Sullivan, J. S. Cohn, K.-A. Rye, et al. Plasma PCSK9 Concentrations Correlate with LDL and Total Cholesterol in Diabetic Patients and Are Decreased by Fenofibrate Treatment Clin. Chem., June 1, 2008; 54(6): 1038 - 1045. [Abstract] [Full Text] [PDF]

				S. Kourimate, C. Le May, C. Langhi, A. L. Jarnoux, K. Ouguerram, Y. Zair, P. Nguyen, M. Krempf, B. Cariou, and P. Costet Dual Mechanisms for the Fibrate-mediated Repression of Proprotein Convertase Subtilisin/Kexin Type 9 J. Biol. Chem., April 11, 2008; 283(15): 9666 - 9673. [Abstract] [Full Text] [PDF]

				K. E Liyanage, A. J Hooper, J. C Defesche, J. R Burnett, and F. M van Bockxmeer High-resolution melting analysis for detection of familial ligand-defective apolipoprotein B-100 mutations Ann Clin Biochem, March 1, 2008; 45(2): 170 - 176. [Abstract] [Full Text] [PDF]

				H. E. Careskey, R. A. Davis, W. E. Alborn, J. S. Troutt, G. Cao, and R. J. Konrad Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9 J. Lipid Res., February 1, 2008; 49(2): 394 - 398. [Abstract] [Full Text] [PDF]

				W. E. Alborn, G. Cao, H. E. Careskey, Y.-W. Qian, D. R. Subramaniam, J. Davies, E. M. Conner, and R. J. Konrad Serum Proprotein Convertase Subtilisin Kexin Type 9 Is Correlated Directly with Serum LDL Cholesterol Clin. Chem., October 1, 2007; 53(10): 1814 - 1819. [Abstract] [Full Text] [PDF]